Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: a systematic review

Immune checkpoint inhibitors (ICIs), namely anti- programmed cell death 1 (anti-PD-1), anti- programmed death ligand 1 (anti-PD-L1) and anti- cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), have entered clinical practice for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), either as monotherapy or combined with chemotherapy, warranting long-term survival in a certain proportion of patients [1 –5].

Source: Cancer Treatment Reviews - July 18, 2023 Category: Cancer & Oncology Authors: Ilaria Attili, Antonio Passaro, Carla Corvaja, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Filippo de Marinis Tags: Anti-tumour Treatment Source Type: research